The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.

SwanBio Therapeutics, a US-based gene therapy developer focused on adeno-associated virus-based treatments for inherited neurological conditions, has closed a $56m series B round co-led by Syncona and Mass General Brigham Ventures, the investment arm of health system Mass General Brigham. The Harvard University spinout has bow raised $133m altogether, after Syncona had already contributed to…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.